Literature DB >> 18295156

Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.

Benedetto Vitiello1.   

Abstract

The effects of stimulant medications and atomoxetine on physical growth and on cardiovascular function are reviewed in light of the most recent data, with attention to clinical implications and research needs. Although these medications have a favorable benefit/risk profile and do not induce clinically significant changes in growth or cardiovascular function in the majority of cases, careful patient monitoring is needed to identify individuals at risk for negative outcomes. More research is needed to elucidate the mechanism of growth suppression to estimate better the risk for rare but life-threatening events and test the effectiveness of monitoring procedures.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18295156      PMCID: PMC2408826          DOI: 10.1016/j.chc.2007.11.010

Source DB:  PubMed          Journal:  Child Adolesc Psychiatr Clin N Am        ISSN: 1056-4993


  69 in total

1.  AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs.

Authors:  H Gutgesell; D Atkins; R Barst; M Buck; W Franklin; R Humes; R Ringel; R Shaddy; K A Taubert
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1999-08       Impact factor: 8.829

2.  Combining methylphenidate and clonidine: a clinically sound medication option.

Authors:  T E Wilens; T J Spencer; J M Swanson; D F Connor; D Cantwell
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1999-05       Impact factor: 8.829

3.  Growth rebound after termination of stimulant drugs.

Authors:  D J Safer; R P Allen; E Barr
Journal:  J Pediatr       Date:  1975-01       Impact factor: 4.406

4.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

5.  Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA.

Authors:  B Vitiello; J B Severe; L L Greenhill; L E Arnold; H B Abikoff; O G Bukstein; G R Elliott; L Hechtman; P S Jensen; S P Hinshaw; J S March; J H Newcorn; J M Swanson; D P Cantwell
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

6.  Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial.

Authors:  L L Greenhill; J M Swanson; B Vitiello; M Davies; W Clevenger; M Wu; L E Arnold; H B Abikoff; O G Bukstein; C K Conners; G R Elliott; L Hechtman; S P Hinshaw; B Hoza; P S Jensen; H C Kraemer; J S March; J H Newcorn; J B Severe; K Wells; T Wigal
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

7.  Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.

Authors:  M L Wolraich; L L Greenhill; W Pelham; J Swanson; T Wilens; D Palumbo; M Atkins; K McBurnett; O Bukstein; G August
Journal:  Pediatrics       Date:  2001-10       Impact factor: 7.124

8.  Short-term cardiovascular effects of methylphenidate and adderall.

Authors:  R L Findling; E J Short; M J Manos
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-05       Impact factor: 8.829

9.  Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder.

Authors: 
Journal:  Pediatrics       Date:  2001-10       Impact factor: 7.124

10.  Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems.

Authors:  J R Kramer; J Loney; L B Ponto; M A Roberts; S Grossman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-04       Impact factor: 8.829

View more
  26 in total

1.  [Attention deficit/hyperactivity disorder in childhood and adolescence: from the social construct to pharmacological Calvinism].

Authors:  Javier García Campayo; Marta Alda Díez; Santiago Gascón
Journal:  Aten Primaria       Date:  2012-01-03       Impact factor: 1.137

2.  "A massive long way": interconnecting histories, a "special child," ADHD, and everyday family life.

Authors:  Linda C Garro; Kristin E Yarris
Journal:  Cult Med Psychiatry       Date:  2009-12

3.  Update on therapy for narcolepsy.

Authors:  Michael J Thorpy
Journal:  Curr Treat Options Neurol       Date:  2015-05       Impact factor: 3.598

Review 4.  Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Authors:  Jose Martinez-Raga; Carlos Knecht; Nestor Szerman; María I Martinez
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

5.  ADHD stimulants and their effect on height in children.

Authors:  Ran D Goldman
Journal:  Can Fam Physician       Date:  2010-02       Impact factor: 3.275

6.  A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD.

Authors:  Earle E Bain; Weining Robieson; Yili Pritchett; Tushar Garimella; Walid Abi-Saab; George Apostol; James J McGough; Mario D Saltarelli
Journal:  Neuropsychopharmacology       Date:  2012-10-03       Impact factor: 7.853

7.  Update on adult attention-deficit/hyperactivity disorder.

Authors:  Paul Hammerness; Craig Surman; Katherine Miller
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

8.  Novel and functional norepinephrine transporter protein variants identified in attention-deficit hyperactivity disorder.

Authors:  Maureen K Hahn; Angela Steele; R Steven Couch; Mark A Stein; Jessica J Krueger
Journal:  Neuropharmacology       Date:  2009-08-19       Impact factor: 5.250

Review 9.  Diagnosis and Treatment Options for Preschoolers with Attention-Deficit/Hyperactivity Disorder.

Authors:  Sharon Wigal; Phillip Chappell; Donna Palumbo; Shannon Lubaczewski; Sara Ramaker; Richat Abbas
Journal:  J Child Adolesc Psychopharmacol       Date:  2020-01-20       Impact factor: 2.576

Review 10.  Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.

Authors:  Henry A Spiller; Hannah L Hays; Alfred Aleguas
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.